Pathways Bioscience, LLC
Biotech · Private
Topical oral formulation (PB-001) activating Nrf2 signaling pathway to prevent or treat oral mucositis in cancer patients
- Grants
- $878K
- 4 awards
- Sector median: 1
- Raised
- —
- No Form D on record
- Contracts
- —
- No federal contracts on record
- Patents
- 8
- 2 granted · 6 pending
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓20162017
| Date | Event | Source | Amount |
|---|---|---|---|
| Federal grant· 1 of 2 same day | Department of Health and Human Services · Phase I · A Topical Nrf2 Activator for Oral Mucositis | $229,248 | |
| Federal grant· 2 of 2 same day | Department of Health and Human Services · Phase I · A Topical Nrf Activator for Oral Mucositis | $229,248 | |
| Federal grant | Department of Health and Human Services · Phase I · Supporting Healthy Aging with a Phytochemical Combination that Acts at Multiple Control Points in the Nrf2 Activation Pathway | $209,928 | |
| Federal grant | Department of Health and Human Services · Phase I · Supporting Healthy Aging with a Phytochemical Combination that Acts at Multiple Control Points in the Nrf Activation Pathway | $209,928 |
Federal grant · SBIR/STTR
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 2994 | TRIMTECH | — | — |
| 2995 | NeuroCycle Therapeutics, Inc. | — | — |
| 2996 | PROVAIDYA | — | — |
| 2997 | Pathways Bioscience, LLC | — | — |
| 2998 | End2End Genomics LLC | — | — |
| 2999 | Tolerance Bio Inc. | — | $15M |
| 3000 | IMMUNOBLUE, LLC | — | — |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Patents
- Compositions For Improved NRF2 Activation And Methods Of Their Useapplication
- Compositions and Methods for Treatment or Prevention of Oral Mucositisapplication
- Compositions and Methods for Treatment or Prevention of Oral Mucositisgranted
- Compositions For Improved NRF2 Activation And Methods Of Their Useapplication
- Compositions For Improved NRF2 Activation And Methods Of Their Usegranted
- Compositions And Methods For Treatment Or Prevention Of Oral Mucositisapplication
- Compositions And Methods For Treatment Or Prevention Of Oral Mucositisapplication
- Compositions For Improved NRF2 Activation And Methods Of Their Useapplication
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.